GlassScriptPhysician profile
Jorge Velez Garza
NPI 1992017727
$1,387.80
in general payments reported to CMS, 2019-2025
9 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.27 · 2020: $39.91 · 2022: $170 · 2023: $344 · 2024: $275 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $458.24 | 2023-2025 | Ruby Coil, Indigo System |
| Abbott Laboratories | $195.25 | 2022-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $147.94 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $134.01 | 2025 | |
| Novo Nordisk INC | $126.68 | 2019-2024 | Sogroya, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Dexcom, INC. | $115.28 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $53.44 | 2019-2020 | |
| Ardelyx, INC. | $31.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Velez Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.